The 0.9 kg figure buried in Lilly’s ATTAIN-MAINTAIN results is the number that reframes the entire oral-versus-injectable debate in obesity maintenance. Participants who plateaued on Wegovy at maximum tolerated dose and then switched to Foundayo — a once-daily oral GLP-1 — held their weight almost perfectly over 52 weeks, losing only 0.9 kg of previously achieved reduction. That is not a rounding error. That is a demonstration that the oral formulation, when deployed specifically as a maintenance tool after injectable induction, can approximate injectable continuity in a population that has already done the hard metabolic work.
The design logic here deserves scrutiny. Both ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN used a sequential, switch-based architecture rather than a head-to-head induction model, which means the trials were built to answer a very specific clinical question: what happens after you have already achieved weight loss and need a durable, potentially lower-burden maintenance option? SURMOUNT-MAINTAIN’s dose-reduction arm answers a separate but related question — Zepbound 5 mg maintained all but 5.6 kg versus zero loss in the MTD continuation arm, a 5.6 kg penalty for stepping down. That gap is real, but it sits against a backdrop of 22–24 kg of total prior loss, making it a proportionally modest trade-off for patients who cannot tolerate or access higher doses. The placebo comparators in both trials lost weight rapidly upon discontinuation, reinforcing that any active maintenance, oral or injectable, beats none.
Tolerability held up under the switch conditions. Foundayo’s nausea rate of 18.8% in ATTAIN-MAINTAIN is not trivial, but discontinuation rates due to adverse events were actually lower in the Foundayo arm from Zepbound (7.2%) than in the placebo arm from the same prior therapy (6.3%) — a near-wash that suggests tolerability concerns are manageable in a maintenance context rather than a naive first-exposure one. Zepbound 5 mg during the SURMOUNT-MAINTAIN maintenance period produced zero discontinuations due to adverse events, which is a remarkably clean safety signal for a chronic therapy.
The single endpoint to watch from here is whether FDA accepts ATTAIN-MAINTAIN as sufficient support for a formal maintenance indication label for Foundayo — because that label language, if it specifies post-injectable-induction use, determines exactly how payers construct step-therapy criteria and prior-authorization sequences for the oral GLP-1 class.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
